Association of TNF-α –308G/A, SP-B 1580 C/T, IL-13 –1055 C/T gene polymorphisms and latent adenoviral infection with chronic obstructive pulmonary disease in an Egyptian population

Nada Ezzeldin1, Alaa Shalaby2, Amal Saad-Hussein3, Howayda Ezzeldin4, Dalia El Lebedy4, Hebatallah Farouk4, Dina M. Kandil4

Abstract

Introduction: Chronic obstructive pulmonary disease (COPD) is a leading cause of disability and death. The most common cause of COPD is smoking. There is evidence suggesting that genetic factors influence COPD susceptibility and variants in several candidate genes have been significantly associated with COPD. In this study, we aimed to investigate the possible association of the TNF-α –308, SPB+1580, IL-13 –1055 gene polymorphisms and latent adenovirus C infection with COPD in an Egyptian population.

Material and methods: Our study included 115 subjects (75 smokers with COPD, 25 resistant smokers and 15 non-smokers) who were subjected to spirometric measurements, identification of adenovirus C and genotyping of TNF-α –308G/A, SP-B+1580 C/T and IL-13 –1055 C/T polymorphisms by real-time PCR.

Results: The adenovirus C gene was identified in all subjects. The distribution of TNF-α genotypes showed no significant differences between different groups. However, homozygous A genotype was associated with a significant decrease in FEV1, FEV1/FVC and FEF25/75% of predicted in COPD (p < 0.05). As regards SP-B genotypes, resistant smokers had a significantly higher homozygous T genotype frequency compared to COPD and non smokers (p = 0.005). Interleukin 13 genotypes showed no significant difference between different groups. There was a significant decrease in FEF25/75% of predicted in T allele carriers in COPD patients (p = 0.001).

Conclusions: The COPD is a disease caused by the interaction of combined genes and environmental influences, in the presence of smoking and latent adenovirus C infection, TNF-α –308A, SPB +1580 T and IL-13 –1055 T polymorphisms predispose to the development of COPD.

Key words: single nucleotide polymorphism, smoking, adenovirus C, chronic obstructive pulmonary disease.

Introduction

Chronic obstructive pulmonary disease (COPD) is a complex mix of signs and symptoms in patients with chronic bronchitis and emphysema that largely results from cigarette smoking [1]. Several lines of evidence strongly suggest that genetic factors influence COPD susceptibility as well; severe
α1-antitrypsin deficiency is one of the proven genetic determinants of COPD [2]. Variants in several candidate genes have been significantly associated with COPD, suggesting an interaction between genetic and environmental influences [3].

Transforming growth factor-β1 (TGF-β1) is a reasonable pathophysiological candidate gene which has been associated with COPD [4]. In a case control study, the distribution of TGF-β1 genotypes in an Egyptian population was demonstrated; the absence of the Pro-Pro alleles in all cases of the study denoted a high predisposition to COPD in Egyptian smokers. Moreover, the Pro allele of the TGF-β1 gene was expressed more commonly in resistant smokers than in smokers who developed COPD, demonstrating a protective role against COPD and an important effect in preserving further decline in forced expiratory volume in the 1 s (FEV1) [5].

Tumour necrosis factor α (TNF-α), a proinflammatory cytokine, has many effects relevant to the pathogenesis of COPD, including neutrophil release from the bone marrow and neutrophil activation [6]. Enhanced levels of TNF-α have been detected in sputum [7] and in circulation [8] of COPD patients, indicating that this cytokine is involved in both the local and systemic inflammation present in COPD. Analysis of possible TNF-α gene polymorphisms in COPD could be related to a higher susceptibility to develop this disabling pathological condition. An association between the TNF-α –308G/A polymorphism and COPD was reported in Taiwanese [9] and Japanese populations [6].

Surfactant protein B (SP-B) polymorphisms have been associated with COPD susceptibility in the presence of a gene-environment interaction [10].

Interleukin 13 (IL-13) is strongly implicated in the development of asthma and COPD, overexpression of IL-13 in the adult murine lung caused emphysema, elevated mucus production, and inflammation reminiscent of human COPD [11]. An increased frequency of the –1055 T allele in COPD patients compared to healthy controls and smokers with normal lung functions was previously reported, implicating a functional role of IL-13 promoter polymorphism in enhanced risk of COPD development [12].

Adenovirus infection is an common cause of bronchiolitis in children and young adults [13] that could predispose to COPD in adulthood [14]. In particular, group C adenovirus is endemic, and exposure to infection during childhood could lead to latent infection that persists in the lung [15], tonsils [16], and peripheral blood lymphocytes [17]. The COPD is characterized by cough, sputum production, peripheral airways obstruction, and emphysematous destruction of the lung surface area. All these components have been related to an inflammatory process located in the conducting airways and lung parenchyma [18].

In this study we aimed to investigate the possible association of TNF-α –308G/A, SP-B+1580 C/T, IL-13 –1055 C/T gene polymorphisms and latent adenoviral infection with COPD in an Egyptian population.

Material and methods

This was a cohort study; all subjects were selected randomly from the Chest Outpatient Clinic and Pulmonary Function Unit in the National Research Centre and Chest Department of Cairo University over 24 months.

Our study included 115 male subjects. Their age ranged between 40 and 78 years. They were divided into non-COPD groups, group 1 (non-smokers) which included 15 non-smoker healthy controls with normal spirometry and group 2 (resistant smokers) which included 25 smokers who did not develop COPD proved clinically and by normal spirometry, and a COPD group (group 3) which included 75 smokers with COPD.

Patients were assigned to the study according to one or more of the following criteria: age above 40 years, smoking history above 20 pack years, clinical and radiological examination fulfilled the diagnostic criteria of COPD [19]. Exclusion criteria included diseases other than COPD and working in industrial areas. All patients gave written informed consent; the study was approved by the ethical committee of the National Research Centre.

All subjects of the study were subjected to medical history taking, clinical examination, plain chest X-ray postero-anterior view, and pre- and post-bronchodilator spirometric measurements of FEV1, FEV1/FVC (forced vital capacity) and forced expiratory flow (FEF) 25/75% of predicted. Normal pulmonary function test (PFT) was considered as FEV1 % of predicted > 85%, FEV1/FVC % of predicted > 70%. Bronchodilators were stopped 24 h before PFT.

Thirteen of our COPD patients were admitted to the ICU for acute (on top of chronic) respiratory failure, so spirometric measurements were not performed on them.

Laboratory methods

Identification of adenovirus C gene and genotyping of TNF-α, SP-B, and IL-13 gene single nucleotide polymorphisms (SNPs) were done by real-time polymerase chain reaction (real-time PCR).

Genomic DNA extraction

Blood samples were collected using EDTA containing blood tubes and treated with sucrose lysis buffer and the nuclear cell pellets were stored at –80°C until DNA extraction. Genomic DNA was extracted from whole blood using the QIAamp DNA extraction kit (Qiagen Hilden, Germany, Cat
Identification of adenovirus C gene by real-time PCR

The sequence of the Adenovirus C (Adv5) gene (Bank Accession No: NC_001406) was amplified by real-time PCR. Primers used were:
Forward primer 5’GGTTTCTGGAGACATCTCAAAGG[GC/T]GGAGGAGAGGGCA (VIC/FAMGGAAAAGGCGACCA) for IL-13-1055C/T (rs1800925 in the NCBI, SNP database), surfactant protein B +1580 C/T, and GAGGGAAGAGCA (VIC/FAMGGAAAAGGCGACCA) for IL-13-1055C/T, CTTGTTGTAGTCTCTGTAGTATC3’.

Real-time PCR was conducted using SYBR green nucleic acid dye in Light Cycler. The reactions were carried out in a capillary tube with 20 μl reaction volume containing 7 μl of H2O, 1 μl of forward primer, 1 μl of reverse primer, 9 μl of SYBR green master mix and 2 μl of extracted DNA. The following thermocycling profile was used for each reaction: 50°C for 2 min to activate uracil N-glycosylase in the master mix, 95°C for 10 min to activate enzyme followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Disassociation analysis was run at the end of each SYBR green real-time PCR reaction to verify a single PCR amplicon.

Genotyping of IL-13, SP-B and TNF-α SNPs by real-time PCR

The studied SNPs were IL-13 –1055 C/T (rs1800925 in the NCBI, SNP database), surfactant protein B +1580 C/T (rs2118177), and TNF-α –308 G/A (rs1800629). The surrounding sequences of these SNPs were: GGGTTTCTGGAGACATCTCAAAGG[GC/T]GGAGGAGAGGGCA (VIC/FAMGGAAAAGGCGACCA) for IL-13-1055C/T, CTTGTTGTAGTCTCTGTAGTATC3’ for SP-B +1580 C/T, and GAGGGAAGAGCA (VIC/FAMGGAAAAGGCGACCA) for TNF-α –308 G/A.

Amplification of the adenovirus C gene and genotyping SNPs were conducted for a 40-cycle amplification (10 min at 95°C, 15 s at 92°C and 1 min at 60°C) using 11.25 μl of genomic DNA diluted in dH2O, 12.5 μl of Taqman universal PCR Master Mix containing 2.5 mM MgCl2, 25 mM dNTP, 2.5 mM MgCl2 and 1 unit of Taq polymerase universal PCR Master Mix containing 2.5 mM dNTP, and the probe sequence was as follows: AGAAACTTCCAGCCCATGACGGCC.

The study included 115 male subjects. The age and the smoking history in the resistant smokers group and COPD patients group were matched without significant differences (Table I).

The mean values of the post-bronchodilator FEV1, FEV1/FVC and FEF25/75% of predicted in COPD patients group were 47.3%, 59.0% and 29.2%, respectively. They were significantly lower than in non-smokers (86.6%, 85.4% and 81.8%, respectively) and resistant smokers (93.1%, 87.7% and 84.4%, respectively) with value of p < 0.0001 (Table II).

As regards the adenovirus C gene, it was identified in all subjects of the study (Figure 1).

The genotype distribution of the TNF-α –308 G/A polymorphism was heterozygous in 13 cases and homozygous A in 102 cases. The frequency of the homozygous A genotype was 90.6% of COPD, 86.7% of non-smokers and 84% of resistant smokers, with no statistical significant difference between the 3 groups. Homozygous G genotype was not detected in any of our subjects (Table IV).

The genotype distribution of the SP-B +1580 C/T polymorphism showed that the resistant smokers had a significantly higher frequency of homozygous T than either COPD patients or non-smokers (p = 0.005). However, homozygous C genotype frequency was higher in COPD patients than in either resistant smokers or non-smokers, p = 0.005 (Table IV).
Table I. Statistical analysis of age (years) and smoking history (pack years) between the 3 groups

| Parameter               | Group | N° | Mean ± SD | ANOVA          |
|-------------------------|-------|----|-----------|----------------|
|                         |       |    |           | F-ratio        | Value of p |
| Age [years]             | 1     | 15 | 57.0 ± 1.51 | 0.483          | NS          |
|                         | 2     | 25 | 55.3 ± 7.10 |                |             |
|                         | 3     | 75 | 56.7 ± 7.34 |                |             |
| Smoking history (pack years) | 1     | 15 | 0.0 ± 0.00 | 3.452*          | NS          |
|                         | 2     | 25 | 41.6 ± 13.09 |                |             |
|                         | 3     | 75 | 50.1 ± 21.51 |                |             |

*Independent t-test. Group 1 – non-smokers, group 2 – resistant smokers, group 3 – COPD

Table II. Statistical analysis of FEV1%, FEV1/FVC% and FEF25/75% of predicted between the 3 groups

| Parameter               | Group | N° | Mean ± SD | ANOVA          |
|-------------------------|-------|----|-----------|----------------|
|                         |       |    |           | F-ratio        | Value of p |
| FEV1%                   | 1     | 15 | 86.6 ± 22.43 | 81.128         | < 0.0001 (2) |
|                         | 2     | 25 | 93.1 ± 10.12 |                |             |
|                         | 3     | 62 | 47.3 ± 17.41 |                |             |
| FEV1/FVC%               | 1     | 15 | 85.4 ± 3.70 | 62.446         | < 0.0001 (2) |
|                         | 2     | 25 | 87.7 ± 5.98 |                |             |
|                         | 3     | 62 | 59.0 ± 15.10 |                |             |
| FEF25/75%               | 1     | 15 | 81.8 ± 14.25 | 109.09         | < 0.0001 (2) |
|                         | 2     | 25 | 84.4 ± 21.22 |                |             |
|                         | 3     | 62 | 29.2 ± 17.46 |                |             |

FEV1 – forced expiratory volume in the 1 s, FVC – forced vital capacity, FEF – forced expiratory flow, group 1 – non-smokers, group 2 – resistant smokers, group 3 – COPD

Table III. Correlations between FEV1%, FEV1/FVC% and FEF25/75% of predicted with age (years) and smoking history (pack years)

| Parameter               | Group 1 | Group 2 | Group 3 |
|-------------------------|---------|---------|---------|
|                         | Age [years] | Smoking history | Age [years] | Smoking history | Age [years] | Smoking history |
| FEV1%                   | −0.3    | (a)     | −0.2    | −0.3    | −0.3    |
| Sig. (2-tailed) | NS      | NS      | NS      | < 0.05  | < 0.01  |
| FEV1/FVC%               | 0.2     |         | −0.2    | 0.3     | −0.4    | −0.4    |
| Sig. (2-tailed) | NS      | NS      | NS      | < 0.005 | < 0.005 |
| FEF25/75%               | 0.05    |         | −0.2    | 0.005   | −0.3    | −0.2    |
| Sig. (2-tailed) | NS      | NS      | NS      | < 0.05  | NS      |

(a) Cannot be calculated, smoking history is zero; group 1 – non-smokers, group 2 – resistant smokers, group 3 – COPD

Significant difference between the studied groups although there was a high frequency of the homozygous T genotype in COPD patients (20%) compared to the resistant smokers (2.8%) and non-smokers (6.7%) (Table IV, Figure 4). Figure 5 shows the frequencies of different genotypes in different studied groups.

The post-bronchodilator FEV1% of predicted was significantly decreased in TNF-α homozygous A genotype (86.75) compared to heterozygous G/A genotype (93.0%) in resistant smokers (p < 0.05) (Table V). In COPD patients, there was a statistically significant decrease in the mean values of the post-bronchodilator FEV1, FEV1/FVC and FEF25/75% of predicted in homozygous TNF-α A genotype (45.3%, 57.6% and 27.4%, respectively) compared to that in heterozygous G/A genotype (70.2%, 69.4% and 49.8%, respectively), p < 0.05 (Table V). In addition, the mean values of the post-bronchodilator FEV1...
and FEV$_1$/FVC% of predicted were significantly decreased in SP-B homozygous T genotypes (40.9% and 54.1%, respectively) and homozygous C genotype (43.3% and 55.1%, respectively) compared to those in heterozygous C/T genotype (58.4% and 68.5%, respectively, $p < 0.005$) (Table VI). Meanwhile, the mean values of the post-bronchodilator FEF25/75% of predicted was significantly decreased in IL-13 homozygous T and C/T genotypes (17.1% and 27.4%, respectively) compared to homozygous C genotype (37.6%), $p = 0.001$ (Table VII).

**Discussion**

This study selected randomized samples of subjects of the same sex and race. The mean age of the subjects and their smoking index were statistically matched. All subjects were of Caucasian origin; it was found that the frequency of an allele can vary in different racial groups [3].

The mean values of the post-bronchodilator FEV$_1$, FEV$_1$/FVC and FEF25/75% of predicted showed significant negative correlations with age and were significantly reduced in COPD patients compared to non-COPD groups ($p < 0.0001$). Our subjects had a heavy smoking history of more than 20 pack years. Mean values of the post-bronchodilator FEV$_1$, FEV$_1$/FVC% of predicted had significant negative correlations with their smoking history.

Adenovirus C infects more than 80% of the human population early in life [20]. Moreover, near-

| Parameter       | Group 1 (n = 15) | Group 2 (n = 25) | Group 3 (n = 75) | $\chi^2$ | Value of $p$ |
|-----------------|------------------|------------------|------------------|----------|--------------|
| TNF-α –308      |                  |                  |                  |          |              |
| G/A (n = 13)    | Count 2          | 4                | 7                | 0.816    | NS           |
|                 | % within groups 13.3 | 16               | 9.4              |          |              |
|                 | A/A (n = 102)    | Count 13         | 21               | 68       |              |
|                 | % within groups 86.7 | 84               | 90.6             |          |              |
| SPB+1580        |                  |                  |                  |          |              |
| C/T (n = 41)    | Count 6          | 8                | 27               | 14.74    | 0.005        |
|                 | % within groups 40 | 32               | 36               |          |              |
|                 | T/T (n = 40)     | Count 4          | 16               | 20       |              |
|                 | % within groups 26.7 | 64               | 26.7             |          |              |
|                 | C/C (n = 34)     | Count 5          | 1                | 28       |              |
|                 | % within groups 33.3 | 4                | 37.3             |          |              |
| IL-13 –1055     |                  |                  |                  |          |              |
| C/T (n = 45)    | Count 5          | 11               | 29               | 3.493    | NS           |
|                 | % within groups 33.3 | 44               | 38.7             |          |              |
|                 | T/T (n = 18)     | Count 1          | 2                | 15       |              |
|                 | % within groups 6.7 | 8                | 20               |          |              |
|                 | C/C (n = 52)     | Count 9          | 12               | 31       |              |
|                 | % within groups 60 | 48               | 41.3             |          |              |

*Likelihood ratio
ly 100% of adults have serum antibody to multiple serotypes — a finding indicating that infection is common in childhood [21].

In a study that included 60 children presenting with recurrent upper and/or lower respiratory tract infection done in the National Research Centre of Egypt, it was demonstrated that passive cigarette smoking remains an enormous health problem and is a principal cause of recurrence of respiratory infections in children, mainly adenovirus C infection. High prevalence and persistence of adenovirus C infection, exceeding 96% of cases, were demonstrated in children by positive serum IgG and documented by latent gene expression [22].

In our study, identification of adenovirus C in COPD and non-COPD subjects demonstrated the persistence of latent infection during childhood and confirmed our previous study in children. Although cigarette smoking is the major risk factor for the development of COPD, only 15% to 20% of all smokers develop airway obstruction [23]. Therefore, adenovirus that remains from a previous infection of the lungs in a smoker may enhance the inflammatory process in their lungs [24]. The correlation between adenovirus C, COPD and deterioration of pulmonary function was not demonstrated in this study, because all included subjects were positive for adenovirus C and genotyping was not done.

Latent adenoviral infection contributes to chronic airway inflammation through E1A-dependent NF-κB (nuclear factor-κB) activation. It was found that E1A regulation of the lipopolysaccharide (LPS) response may play a role in acute exacerbations as a consequence of bacterial infections in COPD. Adenovirus E1A 13S (adenovirus early gene product)
stimulates the TNF gene in inflammatory cell lines. Moreover, it could contribute to airway remodeling in COPD by the viral E1A gene, inducing transforming growth factor-β1 (TGF-β1) and connective tissue growth factor (CTGF) expression and shifting cells to a more mesenchymal phenotype [25].

The TNF-α mediated inflammation is thought to play a key role in both the respiratory and systemic features of COPD. Single nucleotide polymorphism (SNP) in the promoter region of the TNF-α gene (G→A at position –308) directly affects gene regulation, and is associated with high TNF-α production [26].

In the present study, the genotype distribution of TNF-α –308 polymorphism in Caucasian populations was heterozygous G/A in 13 cases (11.3%) and homozygous A in 102 cases (88.7%). Homozygous alleles G/G were not detected in the studied groups. The TNF-α –308A allele frequency ranged from 10% [27] to 17% [28] in the white population, and from 5% [9] to 8% [6] in the Asian population. The possible cause of this discrepancy may be an ethnic difference affecting prevalence.

In contrast to these studies on white subjects, two studies on Asian subjects showed an association of TNF-α –308G/A polymorphism and COPD [6, 9]. Alternatively, the allele could be in linkage disequilibrium with another gene that increases susceptibility to COPD in smokers only in the Asian population [34].

On the other hand, the homogenous A genotype in COPD patients in the current study was accompanied by a statistically significant reduction in the mean values of the post-bronchodilator FEV1, FEV1/FVC and FEF25/75% of predicted compared to heterozygous G/A genotypes in COPD (p < 0.05). Our findings agreed with those of Keatings et al. [29], who demonstrated that homozygosity for the A allele predisposes to a worse prognosis for COPD.

The surfactant proteins are hydrophobic proteins that contribute to regulation of surface tension in the alveoli. Components of surfactant also have a role in host defense and control of inflammation. Alterations of surfactant might therefore be a factor in COPD [26].

---

**Table V. Comparison of FEV1%, FEV1/FVC% and FEF25/75% of predicted between different TNF-α –308 genotypes in the 3 groups**

| Group | Genotype | N* | Mean ± SD | T-test | Value of p |
|-------|----------|----|-----------|--------|------------|
| 1 (n = 15) | FEV1% | G/A | 2 | 90.0 ± 7.07 | 0.222 | NS |
| | A/A | 13 | 86.1 ± 24.10 | | | |
| | FEV1/FVC% | G/A | 2 | 82.5 ± 2.12 | 1.21 | NS |
| | A/A | 13 | 85.8 ± 3.74 | | | |
| | FEF25/75% | G/A | 2 | 83.5 ± 6.36 | 0.175 | NS |
| | A/A | 13 | 81.5 ± 15.27 | | | |
| 2 (n = 25) | FEV1% | G/A | 4 | 94.2 ± 12.40 | 0.212 | NS |
| | A/A | 21 | 93.0 ± 9.98 | | | |
| | FEV1/FVC% | G/A | 4 | 93.0 ± 5.12 | 2.065 | 0.05 |
| | A/A | 21 | 86.7 ± 5.68 | | | |
| | FEF25/75% | G/A | 4 | 103.3 ± 22.08 | 2.06 | NS |
| | A/A | 21 | 80.9 ± 19.57 | | | |
| 3 (n = 62) | FEV1% | G/A | 5 | 70.2 ± 6.30 | 3.312 | < 0.005 |
| | A/A | 57 | 45.3 ± 16.61 | | | |
| | FEV1/FVC% | G/A | 5 | 69.4 ± 13.35 | 2.482 | < 0.05 |
| | A/A | 57 | 57.6 ± 14.57 | | | |
| | FEF25/75% | G/A | 5 | 49.8 ± 7.69 | 2.917 | 0.005 |
| | A/A | 57 | 27.4 ± 16.92 | | | |

*Likelihood ratio
The genotype distribution of the SP-B +1580 C/T gene polymorphism showed that the non-smokers had a higher frequency of the heterozygous C/T genotype compared to either resistant smokers or COPD patients. Meanwhile, resistant smokers had a significantly higher frequency of T/T genotype, and C/C genotype was higher in COPD patients ($p = 0.005$).

The allelic variation of SP-B +1580 between smokers (C/C and T/T) and non-smokers (C/T) indicates that these alleles appeared to be “smoking-dependent”. Moreover, the homozygous alleles (C/C and T/T) were associated with significant impairment of pulmonary function in the COPD group compared to that in the heterozygous alleles (C/T).

In contrast to our findings, Guo et al. [35] in a Mexican population with COPD reported that the frequency of the homozygous alleles C/C represented 49% of cases and the heterozygous alleles C/T represented 76% of cases. When both marker alleles were present, the odds ratio (OR) for COPD was considerably increased (OR = 24.3, $p < 0.001$) compared to when both markers were absent. No significant differences were observed when one marker was present and the other was absent (OR for T = 0.73, $p = 0.81$; OR for C = 1.9, $p = 0.31$).

In a study done in a Chinese Han population, it was concluded that the SP-B 1580 T allele was probably associated with increased susceptibility to COPD [36].

### Table VI. Comparison of FEV$_1$, FEV$_1$/FVC% and FEF25/75% of predicted between different Surfactant Protein B+1580 genotypes in the 3 groups

| Group | Genotype | N$^*$ | Mean ± SD | F-ratio | Value of $p$ |
|-------|----------|-------|-----------|---------|--------------|
| 1 (n = 15) | FEV$_1$% | C/C | 5 | 93.8 ± 7.95 | 1.098 | NS |
| | | C/T | 6 | 76.2 ± 33.51 | | |
| | | T/T | 4 | 93.3 ± 5.38 | | |
| | FEV$_1$/FVC% | C/C | 5 | 85.0 ± 3.32 | 0.331 | NS |
| | | C/T | 6 | 84.8 ± 3.31 | | |
| | | T/T | 4 | 86.8 ± 5.25 | | |
| | FEF25/75% | C/C | 5 | 87.4 ± 18.27 | 0.987 | NS |
| | | C/T | 6 | 82.3 ± 14.01 | | |
| | | T/T | 4 | 74.0 ± 6.48 | | |
| 2 (n = 25) | FEV$_1$% | C/C | 1 | 74.6 | 1.913 | NS |
| | | C/T | 8 | 93.2 ± 12.34 | | |
| | | T/T | 16 | 94.3 ± 8.29 | | |
| | FEV$_1$/FVC% | C/C | 1 | 87.2 | 0.007 | NS |
| | | C/T | 8 | 87.9 ± 5.11 | | |
| | | T/T | 16 | 87.6 ± 6.71 | | |
| | FEF25/75% | C/C | 1 | 69.0 | 1.602 | NS |
| | | C/T | 8 | 94.8 ± 30.27 | | |
| | | T/T | 16 | 80.3 ± 14.19 | | |
| 3 (n = 62) | FEV$_1$% | C/C | 25 | 43.3 ± 13.92 | 6.844 | < 0.005 |
| | | C/T | 19 | 58.4 ± 16.13 | | |
| | | T/T | 18 | 40.9 ± 18.10 | | |
| | FEV$_1$/FVC% | C/C | 25 | 55.1 ± 13.25 | 6.429 | < 0.005 |
| | | C/T | 19 | 68.5 ± 14.13 | | |
| | | T/T | 18 | 54.1 ± 14.48 | | |
| | FEF25/75% | C/C | 25 | 24.3 ± 15.37 | 2.648 | NS |
| | | C/T | 19 | 36.3 ± 20.14 | | |
| | | T/T | 18 | 28.3 ± 15.39 | | |
either C/C or T/T) were found to be associated with worse prognosis of COPD.

Studies in transgenic mice have shown that the targeted expression of IL-13 in the adult lung causes emphysema, mucus metaplasia, and inflammation that mirror, in many ways, the lesions seen in human COPD. The IL-13 may play an important role in the pathogenesis of COPD, particularly in patients with asthma-like features [11].

The distribution of the genotype of IL-13 –1055 C/T polymorphism showed no significant difference between the studied groups although there was a higher frequency of homozygous T genotype in the COPD patient group compared to other groups. Also, the homozygous T and heterozygous C/T genotypes were associated with a significant reduction in the mean values of the post-bronchodilator FEV1/FVC% of predicted compared to that in the case of homozygous C genotype in the COPD group (p = 0.001). These results indicate that the T allele is associated with COPD and deterioration of pulmonary functions.

Our results are in accordance with those of van der Pouw Kraan et al., who demonstrated that IL-13 promoter region polymorphism –1055 C→T, associated with increased IL-13 production, is more common in COPD patients [12].

In conclusion, from our results we concluded that COPD is a disease caused by the interaction of combined genes and environmental influences. In the presence of smoking and latent adenovirus C infection, TNF-α –308G/A, SP-B+1580 C/T and IL-13 –1055 C/T gene polymorphisms predispose to the development of COPD and decline of lung functions.

| Group | Genotype | N* | Mean ± SD | F-ratio | Value of p |
|-------|----------|----|-----------|---------|------------|
| 1 (n = 15) | FEV1% | C/C | 9 | 84.2 ± 28.99 | 0.135 | NS |
| | | C/T | 5 | 89.2 ± 6.38 | |
| | | T/T | 1 | 95.0 | |
| | FEV1/FVC% | C/C | 9 | 86.0 ± 2.78 | 0.275 | NS |
| | | C/T | 5 | 84.6 ± 5.50 | |
| | | T/T | 1 | 84.0 | |
| | FEF25/75% | C/C | 9 | 82.8 ± 15.99 | 0.050 | NS |
| | | C/T | 5 | 80.6 ± 13.92 | |
| | | T/T | 1 | 79.0 | |
| 2 (n = 25) | FEV1% | C/C | 12 | 91.8 ± 9.80 | 0.868 | NS |
| | | C/T | 11 | 93.1 ± 10.11 | |
| | | T/T | 2 | 102.0 ± 14.14 | |
| | FEV1/FVC% | C/C | 12 | 89.8 ± 6.11 | 1.471 | NS |
| | | C/T | 11 | 85.7 ± 5.88 | |
| | | T/T | 2 | 85.9 ± 1.20 | |
| | FEF25/75% | C/C | 12 | 78.0 ± 13.46 | 1.072 | NS |
| | | C/T | 11 | 90.4 ± 26.49 | |
| | | T/T | 2 | 90.5 ± 28.99 | |
| 3 (n = 62) | FEV1% | C/C | 25 | 43.4 ± 17.58 | 1.486 | NS |
| | | C/T | 22 | 52.1 ± 17.45 | |
| | | T/T | 15 | 46.7 ± 16.37 | |
| | FEV1/FVC% | C/C | 25 | 61.8 ± 19.38 | 1.487 | NS |
| | | C/T | 22 | 59.5 ± 9.20 | |
| | | T/T | 15 | 53.2 ± 13.07 | |
| | FEF25/75% | C/C | 25 | 37.6 ± 19.48 | 7.754 | 0.001 |
| | | C/T | 22 | 27.4 ± 15.17 | |
| | | T/T | 15 | 17.1 ± 6.11 | |
References

1. Molfino NA. Genetics of COPD. Chest 2004; 125: 1929-40.
2. Silverman EK. Progress in chronic obstructive pulmonary disease genetics. The Proceedings of the American Thoracic Society 2006; 3: 405-8.
3. McCluskey SC, Patel BD, Hinchliffe SJ, et al. Siblings of patients with severe obstruction pulmonary disease have a significant risk of airflow obstruction. Am J Resp Crit Care Med 2001; 164: 1419-24.
4. Wu L, Chau J, Young RP, et al. Transforming growth factor-beta1 genotype and susceptibility to chronic obstructive pulmonary disease. Thorax 2004; 59: 126-9.
5. El Bohy M, Ahmed M, Ezzeldin N, et al. Estimation of TGF-beta1 genotypes in Egyptian smokers: association with FEVI in COPD patients. Arch Med Sci 2010; 6: 71-6.
6. Sakao S, Tatsumi K, Igari H, et al. Association of tumor necrosis factor alpha gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. Am J Resp Crit Care Med 2001; 163: 420-2.
7. Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Resp Crit Care Med 1996; 153: 530-4.
8. Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med 2000; 161: 1179-84.
9. Huang SL, Su CH, Chang SC. Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. Am J Resp Crit Care Med 1997; 156: 1436-9.
10. Hersh CP, Demeo DL, Lange C, et al. Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Resp Cell Mol Biol 2005; 33: 71-8.
11. Zheng T, Zhu Z, Wang Z, et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest 2000; 106: 1081-93.
12. van der Pauw Kraan TC, Kucukaycan M, Bakker AM, et al. Chronic obstructive pulmonary disease is associated with the -1055 IL-13 promoter polymorphism. Genes Immun 2002; 3: 436-9.
13. Edwards KM, Thompson J, Paolini J. Adenovirus infections in young children. Pediatrics 1985; 76: 420-4.
14. Samet JM, Tager IB, Speizer FE. The relationship between chronic obstructive pulmonary disease and HLA A1, B8, and DR3 alleles. J Exp Med 1993; 177: 557-60.
15. Matsusue T, Hayashi S, Kuswara K, et al. Latent adenoviral infection in the pathogenesis of chronic airways obstruction. Am Rev Respir Dis 1992; 146: 177-84.
16. Neumann R, Genersch E, Eggers HJ. Detection of adenovirus nucleic acid sequences in human tonsils in the absence of infectious virus. Virus Res 1987; 7: 93-7.
17. Horvath J, Falkonyay L, Weber J. Group C adenovirus DNA sequences in human lymphoid cells. J Virol 1987; 59: 189-92.
18. Bosken CH, Wiggs BR, Pare PD, et al. Small airway dimensions in smokers with obstruction to airflow. Am Rev Respir Dis 1990; 142: 563-70.
19. American Thoracic Society. COPD criteria of diagnosis. Am J Resp Crit Care Med 1995; 152-77.
20. Garnett CT, Erdman D, Xu W, et al. Prevalence and quantification of species C adenovirus DNA in human mucosal lymphocytes. J Virol 2002; 76: 10608-16.
21. Dolin R. Common viral respiratory infections and severe acute respiratory syndrome (SARS). In: Harrison's internal medicine. 17th ed. McGraw (ed.). Hill Professional 2008; Chapter 179.
22. Ezzeldin N, Motaweh A, Mohsen M, et al. Detection of a latent adenovirus C gene in children with recurrent respiratory tract infection. Passive smoking and infection. Egypt J Chest 2010; 59: 1-7.
23. Fletcher C, Peto RA. Natural history of chronic airflow obstruction. BMJ 1977; 1: 1645-8.
24. Meshi B, Vitalis T, Ionescu D. Emphysematous lung destruction by cigarette smoke: the effects of latent adenoviral infection on the lung inflammatory response. Am J Resp Cell Mol Biol 2002; 26: 52-7.
25. Ogawa E, Mark Elliott W, Hughes F, et al. Latent adenoviral infection induces production of growth factors relevant to airway remodeling in COPD. Am J Physiol Lung Cell Mol Physiol 2004; 286: 189-97.
26. Wood AM, Stockley RA. The genetics of chronic obstructive pulmonary disease. Respir Res 2006; 7: 130.
27. Palazzo C, Gile LS, Zorzetto M, et al. Tumor necrosis factor gene complex in COPD and disseminated bronchiectasis. Chest 2000; 117: 1353-5.
28. Higham M, Pride N, Alikhan A, et al. Tumor necrosis factor-alpha gene promoter polymorphism in chronic obstructive pulmonary disease. Eur Respir J 2000; 15: 281-4.
29. Keatings VM, Cave SJ, Henry MJ, et al. A polymorphism in the tumor necrosis factor-alpha gene promoter region may predispose to a poor prognosis in COPD. Chest 2000; 118: 971-5.
30. The International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437: 1299-320.
31. Sandford AJ, Chagani T, Weil TD, et al. Susceptibility genes for rapid decline of lung function in the Lung Health Study. Am J Resp Crit Care Med 2001; 163: 469-73.
32. Lanus EC, De-Torres JP, Baz-Dávila R, et al. Siblings of patients with severe obstruction pulmonary disease have a significant risk of airflow obstruction. Am J Resp Crit Care Med 2001; 164: 1419-24.
33. Wilson AG, De Vries N, Pociot F, et al. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993; 177: 557-60.
34. Küçükaycan M, Van Krugten M, Pennings H, et al. Tumor necrosis factor-alpha -489G/A gene polymorphism is associated with chronic obstructive pulmonary disease. Respir Res 2002; 3: 29.
35. Guo X, Lin HM, Lin Z, et al. Surfactant protein gene A, B, and D marker alleles in chronic obstructive pulmonary disease. Respir Res 2006; 7: 130.
36. Hu R, Xu Y, Zhang Z. Surfactant protein B 1580 polymorphism is associated with susceptibility to chronic obstructive pulmonary disease in Chinese Han population. J Huazhong Univ Sci Technolog Med Sci 2004; 24: 216-38.